A novel biosensor based on intestinal 3D organoids for detecting the function of BCRP

Abstract Breast cancer resistance protein (BCRP), a key drug efflux transporter, significantly affects the therapeutic efficacy of many drugs. Thus, screening specific BCRP inhibitors and distinguishing between substrates and non-substrates of BCRP are valuable in drug discovery and development. This study presents a novel BCRP biosensor based on intestinal 3D organoids for rapid and sensitive detection of BCRP function. First, the crypts were isolated from mouse small intestine, and cultured in advanced DMEM/F12 medium to develop intestinal 3D organoids. Second, immunohistochemical studies demonstrated that BCRP protein in the organoids presented a similar expression and physiologic position to the small intestinal epithelium. Finally, the cultured organoids were treated in BCRP fluorogenic probe substrate Hoechst 33342 with or without BCRP inhibitor Ko143 and YHO-13177. The fluorescence intensity of Hoechst 33342 released from inner of the organoids was detected by microplate reader and the concentrations were calculated. Ko143 and YHO-13177 significantly inhibited the BCRP-mediated Hoechst 33342 transport in the 3D organoids. Consequently, a rapid and efficient biosensor has been successfully established to study BCRP, especially screening BCRP inhibitors in a high-throughput way.

[1]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[2]  Mehran Yazdanian,et al.  Mechanisms of Transport and Structure-Permeability Relationship of Sulfasalazine and Its Analogs in Caco-2 Cell Monolayers , 2000, Pharmaceutical Research.

[3]  N. Blüthgen,et al.  Oncogenic β-catenin and PIK3CA instruct network states and cancer phenotypes in intestinal organoids , 2017, The Journal of cell biology.

[4]  Mia Pras-Raves,et al.  Interplay between metabolic identities in the intestinal crypt supports stem cell function , 2017, Nature.

[5]  Y. Sugimoto,et al.  Phytoestrogens/Flavonoids Reverse Breast Cancer Resistance Protein/ABCG2-Mediated Multidrug Resistance , 2004, Cancer Research.

[6]  Measurement of Rhodamine 123 in Three‐Dimensional Organoids: A Novel Model for P‐Glycoprotein Inhibitor Screening , 2016, Basic & clinical pharmacology & toxicology.

[7]  S. Bates,et al.  ABCG2: a perspective. , 2009, Advanced drug delivery reviews.

[8]  Y. Sugimoto,et al.  Novel Acrylonitrile Derivatives, YHO-13177 and YHO-13351, Reverse BCRP/ABCG2-Mediated Drug Resistance In Vitro and In Vivo , 2011, Molecular Cancer Therapeutics.

[9]  Uwe Muenster,et al.  Characterization of Substrates and Inhibitors for the In Vitro Assessment of Bcrp Mediated Drug–Drug Interactions , 2008, Pharmaceutical Research.

[10]  H. Clevers,et al.  Single Lgr5 stem cells build crypt–villus structures in vitro without a mesenchymal niche , 2009, Nature.

[11]  J. Schellens,et al.  Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. , 2000, Journal of the National Cancer Institute.

[12]  Fengzhi Li,et al.  New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies , 2015, Journal of Experimental & Clinical Cancer Research.

[13]  S. Rabindran,et al.  Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. , 1998, Cancer research.

[14]  Balázs Sarkadi,et al.  The role of ABC transporters in drug resistance, metabolism and toxicity. , 2004, Current drug delivery.

[15]  L. Doyle,et al.  Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) , 2003, Oncogene.

[16]  Ye Seul Son,et al.  Distinctive genomic signature of neural and intestinal organoids from familial Parkinson's disease patient‐derived induced pluripotent stem cells , 2017, Neuropathology and applied neurobiology.

[17]  G. Szakács,et al.  Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. , 2012, Biochemical pharmacology.

[18]  R. Masereeuw,et al.  Fluorescence-Based Transport Assays Revisited in a Human Renal Proximal Tubule Cell Line. , 2016, Molecular pharmaceutics.

[19]  T. Utsunomiya,et al.  Characterization of a Side Population of Cancer Cells from Human Gastrointestinal System , 2006, Stem cells.

[20]  A. Glynn,et al.  Oleic acid decreases BCRP mediated efflux of mitoxantrone in Caco-2 cell monolayers. , 2012, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[21]  D. Ross,et al.  Reversal of breast cancer resistance protein (BCRP/ABCG2)‐mediated drug resistance by novobiocin, a coumermycin antibiotic , 2004, International journal of cancer.

[22]  J. Schellens,et al.  Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Supratim Choudhuri,et al.  Structure, Function, Expression, Genomic Organization, and Single Nucleotide Polymorphisms of Human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) Efflux Transporters , 2006, International journal of toxicology.

[24]  Mitchell E Taub,et al.  Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2. , 2012, Journal of pharmaceutical sciences.

[25]  B. Bao,et al.  Luteolin reduces obesity-associated insulin resistance in mice by activating AMPKα1 signalling in adipose tissue macrophages , 2016, Diabetologia.

[26]  Mingyao Liu,et al.  A Novel Model of P‐Glycoprotein Inhibitor Screening Using Human Small Intestinal Organoids , 2017, Basic & clinical pharmacology & toxicology.